NeueHealth Inc. Financial Update

NeueHealth Inc., a publicly traded company in the health care sector, recently reported its financial results for the first quarter of 2025. The company, listed on the New York Stock Exchange, experienced a challenging quarter with its GAAP earnings per share (EPS) reported at -$1.80, missing expectations by a significant margin. The revenue for the quarter was $215.79 million, falling short by $54.31 million compared to forecasts.

Despite these financial setbacks, NeueHealth Inc. highlighted positive developments during its Q1 2025 earnings call. The company reported a substantial 51% increase in consumer numbers, indicating strong consumer growth. Additionally, NeueHealth maintained EBITDA profitability, showcasing resilience in its operational performance despite the revenue and expansion challenges faced during the quarter.

The company’s stock, trading under the ticker symbol NEUE, closed at $6.82 on May 6, 2025. Over the past year, the stock has experienced volatility, with a 52-week high of $7.66 on February 17, 2025, and a low of $3.79 on December 19, 2024. As of the latest data, NeueHealth Inc. has a market capitalization of $60,530,000.

The price-to-earnings (P/E) ratio for NeueHealth stands at -0.29667, reflecting the company’s current earnings challenges. Despite these financial hurdles, the company’s focus on consumer growth and operational profitability suggests a strategic emphasis on long-term growth and stability.

In related news, Neue Theory Wellness Corp., a separate entity, announced the launch of its new product, Digest + Debloat, a digestive enzyme supplement aimed at addressing bloating. This product is part of Neue Theory’s broader commitment to gut health as a foundation for overall well-being.